Cutoff Values of MASK-air Patient-Reported Outcome Measures
dc.contributor.author | Sousa-Pinto, B | |
dc.contributor.author | Sa-Sousa, A | |
dc.contributor.author | Vieira, RJ | |
dc.contributor.author | Amaral, R | |
dc.contributor.author | Pereira, AM | |
dc.contributor.author | Anto, JM | |
dc.contributor.author | Klimek, L | |
dc.contributor.author | Czarlewski, W | |
dc.contributor.author | Mullol, J | |
dc.contributor.author | Pfaar, O | |
dc.contributor.author | Bedbrook, A | |
dc.contributor.author | Brussino, L | |
dc.contributor.author | Kvedariene, V | |
dc.contributor.author | Larenas-Linnemann, DE | |
dc.contributor.author | Okamoto, Y | |
dc.contributor.author | Ventura, MT | |
dc.contributor.author | Ansotegui, IJ | |
dc.contributor.author | Bosnic-Anticevich, S | |
dc.contributor.author | Canonica, GW | |
dc.contributor.author | Cardona, V | |
dc.contributor.author | Cecchi, L | |
dc.contributor.author | Chivato, T | |
dc.contributor.author | Cingi, C | |
dc.contributor.author | Costa, EM | |
dc.contributor.author | Cruz, AA | |
dc.contributor.author | Del Giacco, S | |
dc.contributor.author | Devillier, P | |
dc.contributor.author | Fokkens, WJ | |
dc.contributor.author | Gemicioglu, B | |
dc.contributor.author | Haahtela, T | |
dc.contributor.author | Ivancevich, JC | |
dc.contributor.author | Kuna, P | |
dc.contributor.author | Kaidashev, I | |
dc.contributor.author | Kraxner, H | |
dc.contributor.author | Laune, D | |
dc.contributor.author | Louis, R | |
dc.contributor.author | Makris, M | |
dc.contributor.author | Monti, R | |
dc.contributor.author | Morais-Almeida, M | |
dc.contributor.author | Mosges, R | |
dc.contributor.author | Niedoszytko, M | |
dc.contributor.author | Papadopoulos, NG | |
dc.contributor.author | Patella, V | |
dc.contributor.author | Pham-Thi, N | |
dc.contributor.author | Regateiro, FS | |
dc.contributor.author | Reitsma, S | |
dc.contributor.author | Rouadi, PW | |
dc.contributor.author | Samolinski, B | |
dc.contributor.author | Sheikh, A | |
dc.contributor.author | Sova, M | |
dc.contributor.author | Taborda-Barata, L | |
dc.contributor.author | Toppila-Salmi, S | |
dc.contributor.author | Sastre, J | |
dc.contributor.author | Tsiligianni, I | |
dc.contributor.author | Valiulis, A | |
dc.contributor.author | Yorgancioglu, A | |
dc.contributor.author | Zidarn, M | |
dc.contributor.author | Zuberbier, T | |
dc.contributor.author | Fonseca, JA | |
dc.contributor.author | Bousquet, J | |
dc.date.accessioned | 2024-07-18T12:08:59Z | |
dc.date.available | 2024-07-18T12:08:59Z | |
dc.description.abstract | BACKGROUND: In clinical and epidemiological studies, cutoffs of patient-reported outcome measures can be used to classify patients into groups of statistical and clinical relevance. However, visual analog scale (VAS) cutoffs in MASK-air have not been tested. OBJECTIVE: To calculate cutoffs for VAS global, nasal, ocular, and asthma symptoms.METHODS: In a cross-sectional study design of all MASK-air participants, we compared (1) approaches based on the percen-tiles (tertiles or quartiles) of VAS distributions and (2) data -driven approaches based on clusters of data from 2 comparators (VAS work and VAS sleep). We then performed sensitivityanalyses for individual countries and for VAS levels corre-sponding to full allergy control. Finally, we tested the different approaches using MASK-air real-world cross-sectional and lon-gitudinal data to assess the most relevant cutoffs.RESULTS: We assessed 395,223 days from 23,201 MASK-air users with self-reported allergic rhinitis. The percentile-oriented approach resulted in lower cutoff values than the data-driven approach. We obtained consistent results in the data-driven approach. Following the latter, the proposed cutoff differenti-ating controlled and partly-controlled patients was similar to the cutoff value that had been arbitrarily used (20/100). However, a lower cutoff was obtained to differentiate between partly-controlled and uncontrolled patients (35 vs the arbitrarily-used value of 50/100).CONCLUSIONS: Using a data-driven approach, we were able to define cutoff values for MASK-air VASs on allergy and asthma symptoms. This may allow for a better classification of patients with rhinitis and asthma according to different levels of control, supporting improved disease management. (c) 2022 American Academy of Allergy, Asthma & Immunology (J Allergy Clin Immunol Pract 2023;11:1281-9) | |
dc.identifier.issn | 2213-2198 | |
dc.identifier.other | 2213-2201 | |
dc.identifier.uri | http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/11099 | |
dc.language.iso | English | |
dc.publisher | ELSEVIER | |
dc.subject | PERSON-CENTERED CARE | |
dc.subject | ALLERGIC RHINITIS | |
dc.subject | SEVERITY | |
dc.subject | ASTHMA | |
dc.subject | SLEEP | |
dc.title | Cutoff Values of MASK-air Patient-Reported Outcome Measures | |
dc.type | Article |